Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsThe advent of Chimeric Antigen Receptor T-cell (CAR-T) therapies has revolutionized the field of oncology, providing new avenues for treating various forms of cancer. Our 20 years of experience in the biotechnology sector have equipped us with the expertise and technological capabilities to support the entire lifecycle of CAR-T products, from early development to commercialization.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORE
Creative Biolabs offers a comprehensive CAR-T Cell Model Construction and Engineering Service designed to support precision drug screening and immunotherapy discovery. Our platform enables the generation of highly defined CAR-T cell models through site-specific gene integration and high-throughput functional mapping, minimizing off-target effects and ensuring consistent CAR expression. By systematically evaluating CAR architectures, signaling domains, and target engagement, we help identify high-potency lead candidates with optimized persistence and efficacy, particularly for solid tumor applications.
The landscape of CAR-T therapy is evolving from basic modular assembly to complex, high-throughput functional exploration. By implementing high-throughput screening and computational modeling, researchers can now simultaneously investigate hundreds of thousands of domain combinations. These advancements facilitate a deeper understanding of CAR design rules, essential for overcoming the hostile tumor microenvironment in both hematological and solid malignancies.
Fig.1 High-Throughput Screening approaches.1
Our service provides a comprehensive solution for therapeutic developers looking to mitigate the risks associated with random viral integration and unpredictable signaling kinetics. By utilizing site-specific gene editing knock-in protocols, we deliver uniform cell populations that allow for accurate benchmarking of CAR variants. We assist your project by identifying "super-clones" with superior polyfunctional cytokine profiles and real-time cytotoxicity. This data-driven approach ensures that only the most robust candidates proceed to costly in vivo trials, thereby reducing development overhead.
Discover How We Can Help - Request a Consultation.
We offer a suite of mainstream and innovative technology platforms designed to optimize every component of the CAR architecture:
Required Starting Materials: Clients initiate the service by providing target antigen sequences and specific performance criteria, such as desired affinity ranges or target tissue tropism.
Q1: Can this service be adapted for complex solid tumor targets?
A1: Yes. Our platform optimizes CAR "reach" and sensitivity by screening diverse hinge and transmembrane domains, ensuring effective infiltration and activation against solid tumor antigens. Contact us to discuss your specific target.
Q2: Why choose site-specific gene editing technology integration over viral transduction?
A2: Gene editing technology integration at the T cell receptor alpha constant locus ensures uniform CAR expression and prevents insertional mutagenesis. This precision provides cleaner data and minimizes tonic signaling during drug screening.
Q3: How do you minimize off-target toxicity?
A3: We prioritize safety through in silico off-target prediction and experimental validation using unbiased genome-wide analysis to confirm high specificity before clinical progression.
Creative Biolabs offers a comprehensive tumor model portfolio to support streamlined functional CAR-T screening. Our services include diverse solid and hematologic tumor models, enabling rapid evaluation of CAR-T efficacy, specificity, and persistence in translationally relevant systems.
Learn More →Creative Biolabs provides HTS-enabled drug screening services using advanced functional CAR-T models. By integrating high-throughput platforms with physiologically relevant assays, we enable rapid identification of synergistic compounds and optimization of CAR-T performance.
Learn More →Creative Biolabs provides high-throughput epitope mapping services to support functional CAR-T screening. By rapidly identifying optimal antigen epitopes and binding regions, our platform enables precise CAR design, improved specificity, and enhanced antitumor activity across diverse screening models.
Learn More →Creative Biolabs offers an end-to-end, high-precision pipeline for the construction and engineering of CAR-T cell models optimized for drug screening. Our expertise spans from computational in silico design and high-fidelity DNA library synthesis to site-specific genomic integration and multi-parametric functional validation. By bridging the gap between molecular design and functional performance, we provide biopharmaceutical partners with the data-rich insights necessary to identify high-potency leads, enhance T-cell persistence, and mitigate clinical risks.
Our technical team is ready to provide you with the specialized support needed to advance your therapeutic pipeline. For detailed information regarding our CAR-T Cell Model Construction and Engineering Service, or to receive a tailored proposal for your project, please contact us.
Reference
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
